


# First Quarter Report

as of March 31, 2005

April 28, 2005



## Highlights Q1

**Cytos  
Biotechnology  
raised CHF 21.3  
million net in  
capital increase**

### **1) Cytos Biotechnology raised CHF 21.3 million net in capital increase**

On March 11, 2005, Cytos Biotechnology announced that it has entered into an agreement with swissfirst Bank AG according to which the bank agreed to subscribe and purchase in its own name and account 460,000 newly issued shares of Cytos Biotechnology AG. The purchase price was based on the closing price on the SWX Swiss Exchange of March 10, 2005 (CHF 49.50), resulting in net proceeds of CHF 21.3 million. The shares were placed with a small number of institutional investors. The new shares have been issued out of the authorized capital of Cytos Biotechnology AG which was approved by the shareholders at the Annual Shareholders' Meeting on April 27, 2004.

Based on the authorization foreseen in the articles of incorporation, the pre-emptive rights of existing shareholders were excluded in order to allow the company to raise capital in a fast and flexible manner. The share capital of Cytos Biotechnology has been increased by CHF 46,000 (9.9%) from CHF 462,332.90 to CHF 508,332.90 by issuing 460,000 shares with a nominal value of CHF 0.10 each. The new shares were registered in the commercial register of the Canton of Zurich on March 14, 2005 and trading of the new shares began on March 16, 2005 at the SWX Swiss Exchange.

**Positive phase I results for CYT006-AngQb to treat hypertension**

**2) Positive phase I results for Immunodrug™ candidate to treat hypertension**

On February 14, 2005, Cytos Biotechnology announced positive phase I results for the Immunodrug™ candidate CYT006-AngQb, a therapeutic vaccine for the treatment of hypertension. The clinical data were obtained from a pilot study with 16 normotensive volunteers, which was part of the ongoing combined phase I/II clinical study with CYT006-AngQb. The clinical study, which was initiated in December 2004 with 16 normotensive participants, will also include 72 hypertensive participants with mild to moderate hypertension and is designed to evaluate safety, tolerability, and efficacy of the vaccine.

As the phase I data showed, CYT006-AngQb was safe, very well tolerated, and immunogenic. Out of the 16 healthy volunteers, 12 received one injection of the vaccine and 4 received placebo. All 12 participants receiving the vaccine mounted an angiotensin II-specific antibody response, whereas the 4 participants receiving placebo showed no detectable angiotensin II-specific antibodies. This corresponds to an immunological response rate of 100%. Furthermore, in all 12 responding participants, the angiotensin II-specific antibody levels peaked 2-3 weeks after injection and subsequently started to decline as was anticipated from preclinical experiments.

Those promising phase I results mark an important milestone for the Immunodrug™ technology platform of Cytos Biotechnology: it is the first time that clinical results for an Immunodrug™ candidate targeting a self-molecule in humans were obtained. Already one injection of CYT006-AngQb was sufficient to induce an angiotensin II-specific antibody response. Importantly, the antibody response showed the expected pattern with an early peak followed by a decline over time. This is a key safety requirement for the therapeutic vaccines that Cytos Biotechnology is developing, as it could not be accepted that induced antibodies would block self-molecules in the body life-long.

**Cytos Biotechnology and Medarex expand their collaboration for new drug targets**

**3) Cytos Biotechnology and Medarex expand their collaboration for new drug targets**

On April 1, 2005, Cytos Biotechnology and Medarex announced that the two companies have expanded the scope of their collaborative research, development and license agreement for new drug targets. The first agreement between the companies was announced in November 2002 and focused on drug targets for immunological diseases. This new agreement expands the collaboration scope and will include drug targets discovered in other disease areas of interest.

Under the terms of this new agreement, Medarex will acquire the exclusive rights to develop and commercialize monoclonal antibody therapeutics against the collaboration targets. Medarex also receives a first right of negotiation for use of these targets in small molecule drug discovery and as protein therapeutics. In return, Cytos Biotechnology received an upfront payment, and has the opportunity to earn license fees, milestones, and royalties on net sales of products that are successfully brought to market. Cytos Biotechnology also retains rights to develop and commercialize the target proteins discovered for its own Immunodrugs™.



The identification of disease-relevant drug targets is a key first step in successful drug development. Whilst the human genome sequence has been completed, the formidable task of understanding the function of the proteins encoded by the genes is underway. Cytos Biotechnology's protein discovery technology DELphi™ aims at representative production of the proteins encoded by the human genome in a functionally active form and has led to discovery of several disease proteins of potential relevance in major chronic diseases, such as atherosclerosis. By integrating high throughput screening and functional genomics, the parties believe that DELphi™ offers Cytos Biotechnology's partners a competitive edge in the race for new drug targets.

**Presentation of  
CYT002-NicQb  
phase II study  
data at ASCO**

**4) Presentation of clinical phase II study results for nicotine addiction**

Cytos Biotechnology will present the first data of its phase II study with the Immunodrug™ candidate CYT002-NicQb to treat nicotine addiction at the ASCO (American Society of Clinical Oncology) Annual Meeting 2005. The phase II study is a randomized, double-blind and placebo-controlled trial currently ongoing in over 300 smokers. Primary endpoint of the study is continuous abstinence from smoking in months 4, 5, and 6 after treatment start.

The oral presentation will be on Saturday, May 14, 2005 in the Cancer Prevention Session, 1.45pm. The ASCO Annual Meeting takes place in Orlando, USA, May 13-17, 2005.

**Financial situation  
further  
strengthened,  
clinical  
development  
increases burn rate**

**5) Financial results**

Cash and cashable assets increased to an amount of CHF 90.4 million as of March 31, 2005, in comparison to CHF 76.4 million at the end of December 2004. This rise is attributable to the capital increase executed in the first quarter of 2005. The Company issued 460,000 shares, hence receiving CHF 21.3 million net proceeds.

In order to get higher yields than on the money market, CHF 21 million were invested in high grade short- and long-term investments during the first quarter.

Revenues decreased from CHF 2.7 million in the first quarter 2004 by CHF 2.5 million to CHF 0.2 million in the first quarter 2005. The revenue in the first quarter 2005 stemmed solely from licenses, while those in the first quarter 2004 came from the supply of Alzheimer's Immunodrug™ candidate to Novartis. The fluctuation in revenues is not uncommon to biotech companies as the revenues are often linked to up-front fees, milestones and license payments as well as income for delivery of drug substance, which occur sporadically.

Operating costs increased from CHF 6.9 million by CHF 1.6 million to CHF 8.5 million in the first quarter 2005 due to extended clinical trials in comparison with the first quarter 2004.

Net loss in the first quarter 2005 increased by CHF 4.0 million and amounted to CHF 8.1 million, as a result of decreasing revenues and increasing operating costs compared to the first quarter 2004.

Cash burn for operating activities increased from CHF 2.1 million per month in the first quarter of 2004 to CHF 2.6 million per month in the first quarter of 2005 for the same reasons as the costs increased.

# Balance Sheets

## Cytos Biotechnology AG and subsidiaries

Consolidated Balance Sheets as of In thousand Swiss Francs (except for share information)	March 31, 2005 unaudited	December 31, 2004 audited
Current assets:		
Cash and cash equivalents	14,007	21,033
Short-term investments	36,000	28,000
Trade accounts receivable	240	274
Notes receivable acquired	-	3,000
Prepaid expenses and other current assets	1,066	848
<b>Total current assets</b>	<b>51,313</b>	<b>53,155</b>
Long-term assets:		
Property and equipment, net	13,675	14,035
Net pension benefit	2,192	734
Long-term investments	22,994	6,992
Other long-term assets	14,159	14,159
<b>Total long-term assets</b>	<b>53,020</b>	<b>35,920</b>
<b>Total assets</b>	<b>104,333</b>	<b>89,075</b>
Current liabilities:		
Trade accounts payable	2,030	1,213
Accrued payroll and bonuses	1,564	1,026
Current portion of loan	120	118
Other current liabilities and accrued expenses	5,045	4,490
<b>Total current liabilities</b>	<b>8,759</b>	<b>6,847</b>
Long-term liabilities:		
Loan	1,313	1,344
<b>Total long-term liabilities</b>	<b>1,313</b>	<b>1,344</b>
Shareholders' equity:		
Common stock, CHF 0.10 par value, authorized 6,583,329 shares, issued 5,083,329 shares at March 31, 2005; authorized 6,583,329 shares, issued 4,623,329 shares at December 31, 2004	508	462
Legal Reserves	136	136
Additional paid-in capital	190,236	168,859
Treasury stock (2,130 shares at March 31, 2005, and 5,235 shares at December 31, 2004, at cost)	(66)	(158)
Accumulated deficit	(96,410)	(88,272)
Accumulated other comprehensive income (loss)	(143)	(143)
<b>Total shareholders' equity</b>	<b>94,261</b>	<b>80,884</b>
<b>Total liabilities and shareholders' equity</b>	<b>104,333</b>	<b>89,075</b>

See accompanying notes which are an integral part of these condensed interim consolidated financial statements.

# Statements of Operations

## Cytos Biotechnology AG and subsidiaries

<b>Consolidated Statements of Operations</b>	Three months ended <b>March 31, 2005</b> unaudited	Three months ended <b>March 31, 2004</b> unaudited
In thousand Swiss Francs (except for share information)		
Research and collaboration revenues	231	2,667
<b>Total revenues</b>	<b>231</b>	<b>2,667</b>
Research and development	(7,292)	(5,860)
Sales and marketing	(200)	(238)
General and administrative	(1,070)	(975)
Other operating income	169	457
Other operating costs	(98)	(243)
<b>Net operating costs</b>	<b>(8,491)</b>	<b>(6,859)</b>
<b>Operating loss</b>	<b>(8,260)</b>	<b>(4,192)</b>
Financial income	122	100
<b>Net loss</b>	<b>(8,138)</b>	<b>(4,092)</b>
Other comprehensive income (loss), net of tax:		
Currency translation adjustment	0	0
Total other comprehensive income (loss)	0	0
<b>Comprehensive loss</b>	<b>(8,138)</b>	<b>(4,092)</b>
Basic and diluted net loss per share	(1.73)	(1.07)
Weighted average number of shares used in computing basic and diluted net loss per share	4,693,499	3,835,979

See accompanying notes which are an integral part of these condensed interim consolidated financial statements.

# Cash Flows

## Cytos Biotechnology AG and subsidiaries

<b>Consolidated Statements of Cash Flows</b>	Three months ended <b>March 31, 2005</b> unaudited	Three months ended <b>March 31, 2004</b> unaudited
In thousand Swiss Francs		
Cash flow from operating activities:		
Net loss	(8,138)	(4,092)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	618	595
(Gain) loss on sale of property held for sale	-	(8)
(Gain) loss on sale of equipment	(3)	-
(Gain) loss on foreign exchange movements	2	(0)
Stock option compensation cost	41	24
Changes in assets and liabilities:		
Trade accounts receivable	37	(2,647)
Pension benefits	(1,458)	(1,224)
Prepaid expenses and other current assets	(218)	(116)
Trade accounts payable	811	9
Accrued payroll and bonuses	538	288
Other current liabilities and accrued expenses	555	1,290
<b>Net cash (used in) provided by operating activities</b>	<b>(7,215)</b>	<b>(5,881)</b>
Cash flows from investing activities:		
(Increase) decrease in short-term investments	(5,000)	-
(Increase) decrease in long-term investments	(16,002)	-
Purchase of property and equipment	(257)	(408)
Sale of property and equipment	3	-
Sale of property held for sale	-	2,420
<b>Net cash (used in) provided by investing activities</b>	<b>(21,256)</b>	<b>2,012</b>
Cash flows from financing activities:		
Repayment of loan	(29)	-
Proceeds from issuance of common stock	21,632	33,611
Purchase of treasury shares	(144)	(32)
Sale of treasury shares	302	10
Stock issuance costs	(316)	(2,568)
<b>Net cash (used in) provided by financing activities</b>	<b>21,445</b>	<b>31,021</b>
Net effect of currency translation on cash	0	0
Net increase (decrease) in cash and cash equivalents	(7,026)	27,152
Cash and cash equivalents, beginning of period	21,033	37,839
<b>Cash and cash equivalents, end of period</b>	<b>14,007</b>	<b>64,991</b>

See accompanying notes which are an integral part of these condensed interim consolidated financial statements.

## 1) Organization

Cytos Biotechnology AG ("the Company"), a public Swiss biotechnology company, and its subsidiaries (together "the Group") specialize in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the prevention and treatment of chronic diseases and aim at triggering the patient's immune system to induce specific antibody and targeted T-cell responses, which actively fight disease processes.

The Group is subject to risks common to companies in the biotechnology industry, including, but not limited to, uncertainties regarding the effectiveness and safety of new drugs, new and unproven technologies, clinical trials, regulatory approvals, long product development cycles and high failure rates, continuing capital requirements to fund research and development, commercial success and acceptance, patents and legally protected technologies, third party intellectual property rights, dependence on third parties, competition, concentration of operations, product liability insurance, history of operating losses and uncertainty of future profitability, dependence on important employees, environment, health, data protection and safety, lack of experience in marketing and sales, merger with Askliia Holding AG ("Askliia"), volatility of market value, as well as limited liquidity and shares eligible for future sale.

## 2) Basis of presentation

The accompanying unaudited condensed interim consolidated financial statements of the Group have been prepared in accordance with US-GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with US-GAAP have been condensed or omitted.

These unaudited condensed interim consolidated financial statements should be read in conjunction with the audited financial statements and footnotes related thereto for the period ended December 31, 2004, included in the Group's Annual Report. The unaudited interim consolidated financial statements include, in the opinion of management, all adjustments necessary to present fairly the Group's consolidated financial position as of March 31, 2005, and the consolidated results of its operations and cash flows for the three month period ended March 31, 2005. The consolidated results of such interim periods are not necessarily indicative of the results to be achieved for the period ended December 31, 2005.

The unaudited condensed interim consolidated financial statements include the accounts of Cytos Biotechnology AG and its wholly-owned subsidiaries, Mavena AG, Belp, Switzerland, Askliia Holding (Germany) GmbH in Liquidation, Ravensburg, Germany, and Proteome Therapeutics GmbH, Singen, Germany.

All significant intercompany balances and transactions have been eliminated in consolidation.

Certain amounts in the period ended March 31, 2004, financial statements have been reclassified or adjusted to conform with the audited consolidated financial statements and footnotes related thereto for the period ended December 31, 2004, included in the Group's 2004 Annual Report.

### 3) Shareholders' Equity

On March 10, 2005, the Board of Directors decided to increase the common stock of the Company by CHF 46,000 and by 460,000 shares with a nominal value of CHF 0.10 each. Effective March 14, 2005, an increase of CHF 46,000 and 460,000 shares with a nominal value of CHF 0.10 each was registered at the Commercial Register in the Canton of Zurich and subsequently the new shares were issued to new shareholders. The total net proceeds for the issuance of common stock amounted to CHF 21.3 million.

The new shares have been issued out of the authorized capital of Cytos Biotechnology AG which was approved by the shareholders at the Annual Shareholders' Meeting on April 27, 2004.

In connection with the increase in common stock, the Company incurred costs of approximately CHF 0.3 million. The costs have been recorded as a reduction to Additional Paid-in Capital.

### 4) Licensing, Research and Development Collaborations

On January 6, 2005, the Company announced, that Pfizer Inc. ("Pfizer") and the Company signed a research and commercial license option agreement for the testing of Immunodrugs™ for animal health applications. Pfizer gains exclusive access to test two Immunodrug™ candidates in its models and, if the option on the commercial license agreement is executed, exclusive development and commercial rights to these two animal health product candidates of the Company. In return, the Company received an up-front payment for the option and one-time delivery of the technical quality vaccines, and may earn milestones and additional fees on commercial license execution, on technology transfer for GMP manufacturing, on supply of drug substance, and on approval of Immunodrug™ candidates in major markets. After a successful launch of a product, the Company will earn royalties on Pfizer net sales.

In the course of the first quarter the Company and Medarex Inc. ("Medarex") expanded the scope of their collaborative research, development and license agreement for new drug targets. The first agreement between the companies was announced in November 2002 and focused on drug targets for immunological diseases. This new agreement expands the collaboration scope and will include drug targets discovered in other disease areas of interest.

Under terms of this new agreement, Medarex will acquire the exclusive rights to develop and commercialize monoclonal antibody therapeutics against the collaboration targets. Medarex also receives a first right of negotiation for use of these targets in small molecule drug discovery and as protein therapeutics. In return, Cytos Biotechnology received an up-front payment, and has the opportunity to earn license fees, milestones, and royalties on net sales of products that are successfully brought to market. Cytos Biotechnology also retains rights to develop and commercialize the target proteins discovered for its own Immunodrugs™.

In this quarter the Company entered into a non exclusive research license agreement with a large pharmaceutical company for protein expression technology. Under the terms of this agreement Cytos received an up-front fee and has the potential to earn annual license fees starting on the first anniversary of signing the agreement.

## 5) Segment and geographic information

The Group operates in one segment, focusing on the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The Group's executive board reviews the profit and loss of the Group on an aggregated basis and manages the operations of the Group as a single operating segment. The Group currently derives its research and collaboration revenues from research and development collaborations with third parties. Research and collaboration revenues are attributable to individual countries and are based on the location of the customer, while the long-term assets are based on the location of the Group.

The Group's geographic information is as follows:

In thousand Swiss Francs				
<b>March 31, 2005:</b>	Switzerland	USA	Other	Total
Research and collaboration revenues	100	110	21	231
Long-term assets	53,020	-	-	53,020
<b>March 31, 2004:</b>	Switzerland	USA	Other	Total
Research and collaboration revenues	2,579	47	41	2,667
Long-term assets	32,606	-	-	32,606

## 6) Benefit plans

The Group maintains a retirement plan (the "Plan") covering all of its employees in Switzerland including its executive officers. In addition to retirement benefits, the Plan provides death or long-term disability benefit to its employees.

Benefits under the Plan are principally based on contributions, computed as a percentage of salary, adjusted for the age of the employee. In addition, the Plan provides a guaranteed minimum return. Under the agreement, both the Group and the employee share the costs, including contributions, 50/50. Due to the impact of changes in salary, the guaranteed minimum return element and cost sharing arrangement, the Plan is accounted for as a defined benefit plan in accordance with FAS 87.

The component of net periodic benefit cost recognized in the unaudited interim consolidated statements of operations is as follows:

<b>Net Periodic Benefit Cost</b> in thousand Swiss Francs	Three months ended	Three months ended
	<b>March 31, 2005</b>	<b>March 31, 2004</b>
Service cost	230	156
Interest cost	50	36
Expected return on the cash surrender value	(108)	(81)
Amortization of unrecognized net transition obligation	2	2
<b>Net periodic benefit cost</b>	<b>174</b>	<b>113</b>

In the three month period ended March 31, 2005, and 2004, the Group contributed for the annual costs TCHF 1,864 and TCHF 1,518, respectively, to the Plan at a ratio of 50/50 for the cost sharing between the Group and employees. These contributions are recorded as Net Pension Benefit in the Balance Sheet. Up to March 31, 2005, the Group was repaid by its employees TCHF 247 and up to March 31, 2004, TCHF 203 for their 50% of the allocated pro rata contribution.

#### 7) Earnings (Loss) per share

Basic and diluted net loss per share have been computed based upon the weighted average number of common shares outstanding in conformity with Statement of Financial Accounting Standard No. 128. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase, warrants, and convertible securities. All outstanding options to purchase shares of common stock were not included in the computation of the dilutive net loss per share as the effect would have been anti-dilutive.

#### 8) Stock option plans

The Group has elected to apply the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock issued to Employees", (APB 25 and related interpretations) in accounting for its employee stock option plans. Any compensation costs from the granting of stock options to employees is recognized on a straight line basis over the vesting period.

On December 13, 2004, the board of directors approved a new stock option plan ("SOP 2005"), whereas all employees (except the CEO) received options in January 2005. Each option entitles the holder to purchase one share of the Company within five years after the grant date. Options can only be exercised after a cliff vesting period of two years. The exercise price is CHF 44.26 corresponding to the average closing price of the share during the first five trading days in the year 2005. Management believes this represents the best estimate of the fair value of the underlying common stock. Under this program a total of 74,040 shares were granted on January 10, 2005. As the exercise price is lower than the fair market value at the date of grant, the difference between the exercise price and the fair market value times the number of options allocated will be expensed over the vesting period.

On January 8, 2005, consultants were granted 500 options, which are exercisable after a two year cliff vesting period until January 7, 2010. The exercise price is CHF 44.26 for one option, corresponding to the average closing price of the share during the first five trading days in the year 2005.

For all stock options granted the Group expensed TCHF 41 and TCHF 24 for the first quarter of 2005 and 2004, respectively.

Had compensation costs been determined based upon the method of FAS 123, as amended by FAS 148, the estimated fair value of the options would be amortized over the vesting period of the options as compensation expense, the Group's net loss and basic and diluted net loss per share would have been as follows:

In thousand Swiss Francs (except for share information)	Three months ended <b>March 31, 2005</b>	Three months ended <b>March 31, 2004</b>
Net loss as reported	(8,138)	(4,092)
Net loss pro forma	(8,358)	(5,015)
Basic and diluted net loss per share	(1.73)	(1.07)
Pro forma per share	(1.78)	(1.31)

For stock options issued in 2002, 2004 and 2005, which impact the three month period ended March 31, 2005 and 2004 pro forma net loss computation, the following assumptions were used applying the Black-Scholes Option Pricing Model:

Risk-free interest rate:	1.6% - 3.2%
Expected life (in years):	3.5 - 5
Volatility:	41% - 46%
Dividend:	zero

### **9) Short-term investments**

In the course of the first quarter of 2005, the Group invested in a fixed-term time deposit amounting to CHF 10 million. It has a maturity date of September 30, 2005.

### **10) Notes receivable acquired**

As of March 31, 2005, the Group received CHF 3 million for the outstanding note receivable from Vêtoquinol paid back by early redemption.

### **11) Long-term investments**

CHF 16 million were invested in two fixed-term time deposits in the course of the first quarter of 2005. The fixed-term time deposits have maturity dates of June 30, 2006 and December 31, 2006.

### **12) Property and Equipment**

In the course of the first quarter of 2005, the Group invested TCHF 257 into property and equipment. The largest portion was spent on the last payment for the GMP facility in Schlieren. This facility went into operation in January 2005.

### **13) Contingencies and legal proceedings**

The operations and earnings of the Group continue, from time to time and in varying degrees, to be effected by political, legislative, fiscal, regulatory developments and other various risks. The nature and frequency of these developments and events, not all of which are covered by insurance, as well as their effect on future operations and earnings are not predictable.

Askia was involved in (i) various claims and lawsuits arising in the ordinary course of its business and (ii) claims regarding representations, warranties and covenants given by Askia when divesting its business. Some of these Askia claims and lawsuits (including claims regarding representations, warranties and covenants given by Askia when divesting its business) were settled. Other cases of legal disputes, involving subsidiaries of the Askia that were divested prior to the Merger, were transferred as part of the divested business. With regard to two such lawsuits, whereby the plaintiffs claimed CHF 1.3 million and CHF 0.6 million each, Askia agreed to indemnify the acquirer of the divested business for all costs the divested company or the acquirer will incur in connection with these proceedings.

As a consequence of the Merger these liabilities and lawsuits of Askia as well as the other pending and threatened lawsuits and claims of Askia were taken over by the Group. The Group believes that adequate provisions were made to cover the risks associated with these various claims and lawsuits pending or threatened.

(This page has been left blank intentionally)

(This page has been left blank intentionally)

## Disclaimer

### **Cautionary Statement Regarding Forward-Looking Statements**

Certain statements in this Quarterly Report, including but not limited to, statements, estimates and projections of future trends and of the anticipated future performance of Cytos Biotechnology AG and its subsidiaries (together “the Group”) constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievement of the Group, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. The forward-looking statements are based on the Group’s current beliefs and assumptions regarding a large number of factors affecting its business. Such beliefs and assumptions are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Group. There can be no assurance that: (i) the Group has correctly measured or identified all of the factors affecting its business or the extent of their likely impact, (ii) the publicly available information with respect to these factors on which the Group’s analysis is based is complete or accurate, (iii) the Group’s analysis is correct or (iv) the Group’s strategy, which is based in part on this analysis, will be successful. Factors which affect the Group’s business include, but are not limited to, (i) general market, governmental and regulatory trends, (ii) competitive pressures, (iii) technological developments, (iv) effectiveness and safety of the Group’s technology and therapeutics, (v) uncertainty regarding outcome of clinical trials and regulatory approval process, (vi) management changes, (vii) changes in the market in which the Group operates and (viii) changes in the financial position or credit-worthiness of the Group’s customers and partners.

# Shareholder Information

## Stock Exchange Listing

As of March 31, 2005, the registered shares of Cytos Biotechnology AG were listed at the SWX Swiss Exchange (SWX:CYTN). Swiss Security No.: 1 102 521

## Share Register

Aktienregister Cytos Biotechnology AG  
c/o Nimbus AG  
Postfach, CH-8866 Ziegelbrücke

## Capital Structure

Number of registered shares (nominal value CHF 0.10)	5,083,329
Conditional Capital	CHF 46,000
Authorized Capital	CHF 104,000
Free Float	91%

## Investor Contact

Jakob Schlapbach, CFO  
Cytos Biotechnology AG  
Wagistrasse 25  
CH-8952 Schlieren (Zürich)  
Phone: +41 44 733 46 46  
Fax: +41 44 733 47 02  
E-mail: [jakob.schlapbach@cytos.com](mailto:jakob.schlapbach@cytos.com)  
[www.cytos.com](http://www.cytos.com)

## Annual General Shareholders' Meeting for the financial year 2004

Date: May 25, 2005, at 3 pm  
Place: Cytos Biotechnology AG  
Wagistrasse 25, CH-8952 Schlieren (Zurich)

## Company Profile

Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient's immune system to produce desired therapeutic antibody or cytotoxic T-cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug™ platform, Cytos Biotechnology has built a pipeline of 27 different Immunodrug™ candidates in various disease areas, of which five are currently in clinical development. The Immunodrug™ candidates are developed both in-house (24) and together with Novartis (1) and Pfizer Animal Health (2). Founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the company has 110 employees. Cytos Biotechnology AG has been listed on the SWX Swiss Exchange (SWX:CYTN) since October 2002.

